Kornimate/medical-research-clean huggingface dataset:
rural illinois lung cancer screening initiative

Conditions: Lung Cancer

Summary: the role of this observational study is to access the feasibility of providing lung cancer screening using a designated nurse navigator through lung cancer screening clinic. eligible participants will be identified using medical records, eligibility will be confirmed through phone call, screening visits will be scheduled as in-person visit or telehealth visit. computed tomography screening will be performed at an approved center closer to the individuals place of living and results will be discussed during follow-up in-person visit or telehealth visit.

the long-term goal is to establish healthcare practices to increase adherence to lung cancer screening among high-risk individuals. the overall objective in this application is to establish a lung cancer screening initiative to proactively identify and screen eligible patients for ldct using a designated nurse practitioner (np) along with telehealth. the central hypothesis is that use of a designated np along with telehealth will increase lung cancer screening via ldct among high-risk, racial/ethnic minority, and rural/sub-urban patients. the rationale for this proposal is use of a np and telehealth will help overcome the barriers physicians face in identifying eligible patients for ldct including collecting additional information to determine eligibility, discussing the pros and cons of ldct, providing smoking cessation/abstinence counseling, making shared decisions, and documenting this information in the patients' charts. in this prospective cohort study the nurse practitioner (np) will proactively identify eligible individuals for ldct using emrs that are shared across the department of family and community medicine at siu. these patients will be contacted and those agreeing to undergo screening will be given a referral to a nearby ldct center. the np will follow-up with the patients with the results of the ldct and will refer them for further management to their primary care physician. if the results are negative for nodules then they will be followed up on a yearly basis until the participants are older than 80 years or have other life-threatening health issues.

Eligibility criteria:
inclusion criteria: * all individuals 50-80 years of age * 20 pack-year smoking history * currently smoke or have quit within the past 15 years: exclusion criteria: * individuals 49 years and below or 81 years and above * has not smoked in 15 or more years * individuals who develop a health problem that makes them unwilling or unable to have surgery if lung cancer is detected.

Keywords: cancer screening ldct lung cancer
dexamethasone effect on pain and edema following mandibular 3rd molar surgery; pre-operatively vs post-operatively

Conditions: Impacted Third Molar Tooth

Summary: tthis is a comparative clinical study which will be conducted in omfs department of dikiohs, duhs ojha karachi. in this study the investigators will be comparing the effect of dexamethasone on pain and edema when administered pre-operatively vs post-operatively following surgery of impacted lower 3rd molars. time duration of this study will be 2 months. a total of 100 patients will be considered in this study which will be equally divided into two groups; group a and group b (50 in each group).group a will receive dexamethasone 1 hour pre-operatively while group b will receive the same post-operatively. all surgeries will be performed by the same maxillofacial surgeon and duration of surgery will be around 30-45 mins.

to compare the effect of dexamethasone (im; 8mg) administered pre-operatively versus post-operatively on pain and edema following surgical extraction of mesio-angularly impacted mandibular 3rd molars. this is a comparative clinical study. this study will be conducted in oral maxillofacial surgery department of dikiohs, duhs teaching hospital, ojha, karachi, pakistan. time duration of this study will be 2 months. a total of 100 patients will be considered in the study (50 in each group). sample size was calculated through openepi, taking mean values of post-operative 3rd day swelling (cm) of group a (12.15±0.78), group b (13.85±0.78) \[ref #\], 95% confidence interval (two sided) and 80% of the power of the test. the sample size came out to be 8 patients (4 in each group). the sampling technique is convenience sampling. patients will be randomly distributed into two groups; group a \& group b. group a will receive dexamethasone 8mg intra-muscularly 1 hour pre-operatively while group b will receive the same immediately after surgery. all surgeries will be performed by the same maxillofacial surgeon and duration of surgery will be around 30-45 minutes.

Eligibility criteria:
inclusion criteria: * patients coming to dental opd of dikiohs, duhs, ojha with mesioangular impactions * age of patients: 20-50 years exclusion criteria: * patients with known co-morbidities * patients allergic to dexamethasone * patients with history of recent anti-inflammatory drug intake(nsaids, steroids, or antihistamines) * pregnant/lactating females
fmri study of grasping in autistic patients

Conditions: Autistic Disorder

Summary: the aim of the study is to localise brain regions involved in objects recognition, in planification and adjustment of grasping, in prehension with and without eye control. the study is conducted in normal and autistic adults. we hypothesize different activations in these two populations.


Eligibility criteria:
inclusion criteria: * clinical diagnosis of autistic disorder, right-handed, dq\>50 exclusion criteria: * epilepsia, psychotropic drugs
a single-portal endoscopic approach through subcutaneous tunnel for carpal tunnel release

Conditions: Carpal Tunnel Syndrome

Summary: traditional endoscopic release directly accesses the carpal tunnel and thus carries a higher risk of nerve irritability, even nerve injury. based on our anatomical study, the investigators developed a new endoscopic technique through a single-portal palm approach that passes superficially to palmar aponeurosis, and cut the full transverse carpal ligament. the investigators will compared the technique with the standard dual-portal endoscopic technique.

conduct a multi-center, comparison clinical trial according to clinical trial reporting standards (consort). patients in the single-portal group were treated with a single-portal palm approach that passes superficially to palmar aponeurosis and cut the full transverse carpal ligament. the comparison group were treated with chow endoscopic technique. in order to assess efficiency of single-portal palm approach, the investigators will compared the technique with the standard dual-portal endoscopic technique. the study was approved by shenzhen people's hospital and informed consent was signed.

Eligibility criteria:
inclusion criteria: * a confirmed diagnosis of carpal tunnel syndrome based on evidence for surgical treatment issued by the british society for surgery of the hand * symptoms of carpal tunnel syndrome had lasted\>2 months or inadequate responses to the non-surgical treatments≥3 months * moderate to severe symptoms. exclusion criteria: * mild symptoms or prior injuries to the extremity * bilateral wrists involved, a combined nerve compression, gout, diabetes or chronic renal failure.

Keywords: carpal tunnel syndrome carpal tunnel release pain nerve compression syndromes
the effect of dietary salt intake on immune function in patients with multiple sclerosis

Conditions: Multiple Sclerosis

Summary: the purpose of this work is to investigate the influence of dietary salt intake on immune function in multiple sclerosis (ms) subjects and healthy controls. this study primarily tests the hypothesis that higher dietary salt intake will be associated with a higher frequency of pathogenic th17 cells and impaired function of protective regulatory t cells. if a relationship between dietary salt intake and immune function is observed, this study will also test: a) whether this relationship is unique to ms subjects or whether it is also present in healthy controls, and b) whether healthier immune function can be restored by restricting dietary salt intake.

the purpose of this work is to investigate the influence of dietary salt intake on immune function in ms subjects and healthy controls. this study primarily tests the hypothesis that higher dietary salt intake will be associated with a higher frequency of pathogenic th17 cells and impaired function of protective regulatory t cells. if a relationship between dietary salt intake and immune function is observed, this study will also test: a) whether this relationship is unique to ms subjects or whether it is also present in healthy controls, and b) whether healthier immune function can be restored by restricting dietary salt intake. this is a 5-week pilot study of a dietary intervention of 25 subjects with ms or clinically isolated syndrome (cis) by 2010 diagnostic criteria who will be identified and recruited from the yale ms center and/or referred from outside ms centers. 25 age-matched healthy controls will be recruited from friends, family members, spouses and the patient waiting room at the yale ms center.

Eligibility criteria:
inclusion criteria: * male or female adult subjects * ages 18-60, inclusive * diagnosis of cis or ms by 2010 mcdonald criteria (in the case of ms subjects) * naive to fda- approved ms therapies such as glatiramer acetate, interferon-beta, natalizumab, fingolimod, tecfidera, or teriflunomide exclusion criteria: * secondary or primary progressive ms * prior exposure to fda-approved ms therapies or chemotherapies of any kind * known history of autoimmune disease besides ms * known history of renal disease, hypertension or congestive heart failure * currently taking medications that could affect urine sodium excretion (e.g. diuretics or others that act on the renin-angiotensins-aldosterone system)

Keywords: high sodium diet low sodium diet ms
sensible sleep: measuring alarm and snooze behavior in teens using wearables and smartphones

Conditions: Sleep; Sleep Inertia; Stress

Summary: pilot data suggests that working professionals and college students routinely use alarms and snooze. alarm usage and snoozing is associated with several negative health biomarkers including lighter sleep, higher resting heart rate, and reduced sleep duration. it is unclear when this behavior is established, but it is likely in the teenage years when chronic sleep restriction begins to effect a large percentage of americans. we will ask teens about psychological traits (e.g. personality) and snoozing behavior in a repeated measures design. in addition, we will implement a smartphone based intervention which notifies teens when they are awake past their minimum bedtime for adequate sleep. throughout the study, we will monitor sleep and heart-rate via wearable. from this data, we will establish the prevalence of alarm and snoozing behaviors in teens. we will determine what demographic, psychological, and behavioral traits predict snoozing, and if there are any differences in health biomarkers (e.g. sleep duration, resting heart rate)between snooze and/or alarm users. we will use data from the wearables and smartphones to generate features that can detect snoozing, and will validate them against self-report. finally, we seek to determine if alarm and snoozing behavior can be reduced via a smartphone intervention aimed at increasing sleep duration.


Eligibility criteria:
inclusion criteria:english as a primary language - exclusion criteria: -

Keywords: sleep sleep inertia caffeine sleep disturbance snooze alarm
dose-response study of opc-12759 ophthalmic suspension

Conditions: Dry Eye Syndromes

Summary: the purpose of this study is to evaluate the dose-response of opc-12759 ophthalmic suspension in dry eye patients.


Eligibility criteria:
inclusion criteria: 1. outpatient. 2. subjective complaint of dry eye that has been present for minimum 20 months. 3. primary ocular discomfort severity is moderate to severe. 4. corneal - conjunctival damage is moderate to severe. 5. unanesthetized schirmer's test score of 7mm/5minutes or less. 6. best corrected visual acuity of 0.2 or better in both eyes. exclusion criteria: 1. presence of anterior segment disease or disorder other than that associated with keratoconjunctivitis sicca. 2. anticipated use of any topically-instilled ocular medications or patients with cannot discontinue the use during the study. 3. anticipated use of contact lens during the study. 4. any history of ocular surgery within 12 months. 5. female patients who are pregnant, possibly pregnant or breast feeding; 6. known hypersensitivity to any component of the study drug or procedural medications. 7. receipt of any investigational product within 4 months.

Keywords: opc-12759 dry eye syndromes
home-based health management of copd patients

Conditions: Chronic Obstructive Pulmonary Disease

Summary: minnesota healthsolutions corporation (mhs) proposes to develop and evaluate a program to motivate and monitor people with chronic obstructive pulmonary disease (copd) to complete home exercise as part of pulmonary rehabilitation (pr). the proposed system has two components: home-based activity monitoring and health coaching. the investigators will conduct a randomized, wait-list controlled clinical study to evaluate the effects of the activity monitoring system and health coaching on quality of life and daily steps.


Eligibility criteria:
inclusion criteria: * diagnosis of gold stage ii, iii, or iv copd * current or previous smoker with at least 10 pack-years of cigarette smoking * be hospitalized for an exacerbation of copd exclusion criteria: * high likelihood of being lost to follow-up or contact * inability to provide good data or follow commands * inability to do mild exercise
follow-up of rheumatoid arthritis (ra) moderate to low disease activity study

Conditions: Rheumatoid Arthritis

Summary: to continue to assess the clinical safety and efficacy of certolizumab pegol as add-on therapy with stable-dose disease modifying anti-rheumatic drugs (dmards)

this is a phase iiib, multi-centre, open-label, follow-up study to study c87076 \[nct00674362\] designed to continue to assess the safety and efficacy of certolizumab pegol. two different population will enter the study from c87076 \[nct00674362\] and will be treated with certolizumab pegol every two weeks until it is commercially available for the indication of rheumatoid arthritis (ra) in the subject's country or region or until further notice from ucb: population 1: are those subjects who failed to achieve remission at week 20 and/or week 24 and who completed the week 24 assessment of study c86076 \[nct00674362\].the week 24 assessment (visit 14) of c87076 \[nct00674362\] will also be the entry assessment (visit 1) for c87080. the subjects will receive certolizumab pegol 200 mg every two weeks. no induction period will be applied to ensure the blinding of study c87076 \[nct00674362\]. population 2: are those subjects who achieved remission at both week 20 and week 24, flared up between week 24 and week 52 and completed the week 52 assessment in study c87076 \[nct00674362\]. the week 52 assessment (visit 26) of c87076 \[nct00674362\] will also be the entry assessment (visit 1) for c87080. subjects who flared prior to week 48 in the c87076 \[nct00674362\] study will receive certolizumab pegol 200 mg every two weeks in the c87080 study. those who flared at week 48 or week 52, will receive respectively once 400 mg certolizumab pegol or three times 400 mg certolizumab pegol at two weeks interval as part of an induction phase in the c87080 study. thereafter the subject enters the c87080 study and will be further treated with 200 mg certolizumab pegol every two weeks.

Eligibility criteria:
inclusion criteria: * patients with established adult rheumatoid arthritis on disease modifying anti-rheumatic drugs (dmards) therapy who were included in c87076 protocol and: * either failed to achieve remission after 6 months of study treatment * or flared after the 6 months of study treatment and completed the study (c87076 \[nct00674362\]) exclusion criteria: * all the concomitant diseases or pathological conditions that could interfere and impact the assessment of the study treatment * previous clinical trials and previous biological therapy that could interfere with the results in the present clinical trial

Keywords: rheumatoid arthritis moderate to low disease activity certolizumab pegol
cochlear implants in post-lingually children: results after 10 years

Conditions: Deafness; Hearing Impairment

Summary: objectives: to assess a group of post-lingually children after 10 years of implantation with regard to speech perception, speech intelligibility, and academic/occupational status. study design: a prospective transversal study. setting: pediatric referral center for cochlear implantation. patients: ten post-lingually deafened children with nucleus and med-el cochlear implants. interventions: speech perception and speech intelligibility tests and interview. main outcome measures: the main outcome measures were score of hint sentences recognition (silence and noise), speech intelligibility scores(write-down intelligibility and rating scale scores) and academic/ occupational status.


Eligibility criteria:
inclusion criteria: * postlingually deaf * age at cochlear implant: \< 18 years * more than 10 years of cochlear implant use exclusion criteria: * other disabilities

Keywords: cochlear implant children follow up results
long-term safety and tolerability of atacicept (long-term follow-up of participant who participated in address ii)

Conditions: Lupus Erythematosus, Systemic

Summary: this is a multicenter, double-blind, phase 2b, long-term extension (lte) to the address ii core trial (emr 700461-023) (nct01972568), to evaluate long-term safety and tolerability of atacicept in participants with systemic lupus erythematosus (sle). participants who completed the 24-week core study address ii core study (nct01972568) and thus not met any of the discontinuation criteria were invited to enter this long-term extension (lte) study nct02070978.


Eligibility criteria:
inclusion criteria: * participants who had completed the 24-week treatment period of study emr-700461-023 (address ii core trial) * women of childbearing potential who had a negative pregnancy test * other protocol defined inclusion criteria were applied exclusion criteria: * active neurological symptoms of sle that were deemed severe or progressive * diagnosis of any demyelinating disease, such as, but not restricted to, multiple sclerosis (ms) or optic neuritis * pregnancy * active clinically significant viral, bacterial, or fungal infection, or any major episode of infection that in the investigator's opinion makes the participants unsuitable to continued participation in the study * other protocol defined exclusion criteria were applied

Keywords: lupus erythematosus, systemic atacicept 75 and 150 mg lte
study of thymosin α1 to reduce acute pneumonia for bulky none-small cell lung cancer

Conditions: Non-small Cell Lung Cancer

Summary: this phase ii study is to determine the efficacy of thymosin α1 on the frequency of acute pneumonia in non-small cell lung cancer with bulky tumor.

this phase ii study is to determine the efficacy of thymosin α1 on the frequency of radiation pneumonitis in non-small cell lung cancer with bulky tumor. all patients received four cycles of weekly docetaxel (25mg/㎡) and nedaplatin (25mg/㎡)(dp), each of 1 day's duration, combined with split-course thoracic radiotherapy of 51 gy in 17 fractions or 40 gy in 10 fractions as the first course followed by a break of four weeks. patients without disease progression had a dose of 15 gy in 5 fractions or 24 gy in 6 fractions as a boost. patients were further treated with subcutaneous injections of thymosin once a week,1.6mg each time from the start of radiation to 2 months after the end of radiation. toxicities will be graded according to ctcae v. 4.0.

Eligibility criteria:
inclusion criteria: * pathologic confirmation of nsclc. * patients have measurable or evaluable lesions based on the response evaluation criteria in solid tumors (recist) criteria. * unresectable phase iiia-iiic lung cancer confirmed by pet/ct, ct or mri. * whole lung v20\>=35% when giving 60gy which is the minimum dose of radical irradiation. * eastern cooperative oncology group (ecog) performance status 0-1. * previously treated with chemotherapy or treatment-naive * no previous chest radiotherapy, immunotherapy or biotherapy * hemoglobin≥10 mg/dl, platelet≥100000/μl,absolute neutrophil count ≥1500/μl * serum creatinine ≤1.25 times the upper normal limit(unl), or creatinine clearance≥60 ml/min * bilirubin ≤1.5 times unl, ast（sgot）≤2.5 times unl ,alt（sgpt）≤2.5 times unl,alkaline phosphatase ≤5 times unl * fev1 \>0.8 l * cb6 within normal limits * patients and their family signed the informed consents exclusion criteria: * previous or recent another malignancy, except nonmelanoma skin cancer or cervical cancer in situ * contraindication for chemotherapy * malignant pleural or pericardial effusion. * women in pregnancy, lactation period, or no pregnancy test 14 days before the first dose * women who has the probability of pregnancy without contraception * tendency of hemorrhage * in other clinical trials within 30 days * addicted in drugs or alcohol, aids patients * uncontrollable seizure or psychotic patients without self-control ability * severe allergy or idiosyncrasy * not suitable for this study judged by researchers

Keywords: non-small cell lung cancer split-course chemoradiotherapy thymosin a1
safety and efficacy of turoctocog alfa in prevention and treatment of bleeds in previously untreated children with haemophilia a

Conditions: Congenital Bleeding Disorder; Haemophilia A

Summary: this trial is conducted in asia, europe and north america. the purpose of the trial is to evaluate the safety and efficacy of turoctocog alfa in prevention and treatment of bleeds in previously untreated children with haemophilia a.


Eligibility criteria:
inclusion criteria: * age below 6 years * informed consent obtained before any trial-related activities (trial-related activities are any procedure that would not have been performed during normal management of the patient) * male patients diagnosed with congenital severe haemophilia a (fviii level equal to or below 1%) * no prior use of purified clotting factor products (previous exposure, equal to or less than 5 ed to blood components, e.g. cryoprecipitate, fresh frozen plasma, is accepted) including commercially available novoeight® /novoeight® exclusion criteria: * known or suspected allergy to hamster protein or intolerance to trial product(s) or related products * previous participation in this trial defined as withdrawal after administration of trial product * congenital or acquired coagulation disorders other than haemophilia a * any history of factor viii inhibitor * ongoing treatment or planned treatment during the trial with immunomodulatory agents (e.g. intravenous immunoglobulin (ivig), routine systemic corticosteroids)